Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangrui Medicine
Lianyungang, Jiangsu, China
- Ownership
- Private
- Employees
- ~10000
- Development stage
- Other
01
Overview
Hengrui has 23 new molecular entity drugs approved in China, 4 other innovative drugs marketed, and a pipeline of over 90 clinical-stage candidates, with 400 clinical trials ongoing as of 2024. Clinical-phase agents include camrelizumab (anti-PD-1), rezvilutamide (nonsteroidal antiandrogen), fluzoparib (PARP inhibitor), and apatinib (VEGFR2 inhibitor), among others. Recent results include positive outcomes in multiple cancer indications and global expansion of R&D
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesDermatologyCardiovascularOncologyNeurology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateBiologicmRNA-based drugs
- Industry
- Pharma
02
Partnerships
GSK (multi-program R&D partnership established 2025)CStone Pharmaceuticals (2024 China promotion rights for avapritinib)
Beyond the preview
Go deeper on Jiangrui Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangrui Medicine.